Effects of arsenic trioxide, all-trans-retinoic acid and dexamethasone on NB4 cell line

DARU, Journal of Pharmaceutical Sciences

Volumn 18, Issue 4, 2010, Pages 303-309

  Mandegary, A ^a,b   Mehrabani, M ^c  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Central Laboratory   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; ATO; ATRA; Combination therapy; Dexamethasone

Indexed keywords

ARSENIC TRIOXIDE; CD11B ANTIGEN; DEXAMETHASONE; RETINOIC ACID;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL ASSAY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL;

EID: 79251480397     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Beutler E, Lichtman M, Coller B, Kipps T, Seligsohn U. Williams Hematology. 7th edition ed: McGraw-Hill Professional, 2000.
2. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 2008; 111: 2505-2515.
3. Akbari M, Saki G, Sobhani A, Abolhassani F, Salehnia M. The effect of recombinant human leukemia inhibitory factor (rhlif) on in vitro development of mouse 2-cell embryos and their isolated blastomeres. DARU, 2004; 12: 159-164.
4. Ghaffari M.A, Kadkhodaei-Elyaderani M, Saffari M.R, Pedram M. Monitoring of serum nitric oxide in patients with acute leukemia. Iranian Journal of Pharmaceutical Research, 2005; 4: 233-237.
5. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol, 2006; 17: 131-134.
6. Mandegary A, Hosseini R, Ghaffari SH, Alimoghaddam K, Rostami S, Ghavamzadeh A, Ghahremani MH. The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide. Ann Oncol, 2010; 21: 1884-1890.
7. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood, 1997; 89: 3345-3353.
8. Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, de The H. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood, 1998; 91: 4300-4310.
9. Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Rea D, Buzyn A, Tibi A, Lebbe G, Cimerman P, Chomienne C, Fermand JP, de The H, Degos L, Hermine O, Dombret H. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol, 2003; 21: 2326-2334.
10. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol, 2009; 27: 504-510.
11. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH, Waxman S. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood, 2001; 97: 264-269.
12. Larson RS, Tallman MS. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol, 2003; 16: 453-461.
13. Hicsonmez G. The effect of steroid on myeloid leukemic cells: the potential of short-course high-dose methylprednisolone treatment in inducing differentiation, apoptosis and in stimulating myelopoiesis. Leuk Res. 2006; 30: 60-68.
14. Sternsdorf T, Puccetti E, Jensen K, Hoelzer D, Will H, Ottmann OG, Ruthardt M. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol, 1999; 19: 5170-5178.
15. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De The H, Wang ZY, Chen SJ, Chen Z. All-trans retinoic acid/As2O3 combination309yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004; 101: 5328-5335.
16. Yuksel S, Saydam G, Uslu R, Sanli UA, Terzioglu E, Buyukececi F, Omay SB. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leuk Res, 2002; 26: 391-398.
17. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood, 1996; 88: 1052-1061.
18. Chou WC, Jie C, Kenedy AA, Jones RJ, Trush MA, Dang CV. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A, 2004; 101: 4578-4583.
19. Kumar S, Khanduja KL, Verma N, Verma SC, Avti PK, Pathak CM. ATRA promotes alpha tocopherol succinate-induced apoptosis in freshly isolated leukemic cells from chronic myeloid leukemic patients. Molecular and cellular biochemistry, 2008; 307: 109-119.
20. N'Diaye EN, Vaissiere C, Gonzalez-Christen J, Gregoire C, Le Cabec V, Maridonneau-Parini I. Expression of NADPH oxidase is induced by all-trans retinoic acid but not by phorbol myristate acetate and 1,25 dihydroxyvitamin D3 in the human promyelocytic cell line NB4. Leukemia, 1997; 11: 2131-2136.
21. Condino-Neto A, Whitney C, Newburger PE. Dexamethasone but not indomethacin inhibits human phagocyte nicotinamide adenine dinucleotide phosphate oxidase activity by down-regulating expression of genes encoding oxidase components. J Immunol, 1998; 161: 4960-4967.